#BEGIN_DRUGCARD DB02772

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
57-50-1

# ChEBI_ID:
17992

# Chemical_Formula:
C12H22O11

# Chemical_IUPAC_Name:
(2R,3S,4R,5R,6S)-2-{[(2R,3R,4R,5S)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
50121

# Description:
A nonreducing disaccharide composed of glucose and fructose linked via their anomeric carbons. It is obtained commercially from sugarcane, sugar beet (beta vulgaris), and other plants and used extensively as a food and a sweetener. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Sweetening Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
15157941	Aguilera AA, Diaz GH, Barcelata ML, Guerrero OA, Ros RM: Effects of fish oil on hypertension, plasma lipids, and tumor necrosis factor-alpha in rats with sucrose-induced metabolic syndrome. J Nutr Biochem. 2004 Jun;15(6):350-7.
15169967	Fukuchi S, Hamaguchi K, Seike M, Himeno K, Sakata T, Yoshimatsu H: Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats. Exp Biol Med (Maywood). 2004 Jun;229(6):486-93.
15181020	Ten S, Maclaren N: Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39.
8969287	Lombardo YB, Drago S, Chicco A, Fainstein-Day P, Gutman R, Gagliardino JJ, Gomez Dumm CL: Long-term administration of a sucrose-rich diet to normal rats: relationship between metabolic and hormonal profiles and morphological changes in the endocrine pancreas. Metabolism. 1996 Dec;45(12):1527-32.

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
-5.77

# Experimental_LogP_Hydrophobicity:
-3.70

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
2.1E+006 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Sucrose

# HET_ID:
SUC

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C12H22O11/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12/h4-11,13-20H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11+,12+/m0/s1

# InChI_Key:
InChIKey=CZMRCDWAGMRECN-MTNNYNCSSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00089

# KEGG_Drug_ID:
D00025

# LIMS_Drug_ID:
2772

# Mechanism_Of_Action:
Not Available

# Melting_Point:
185.5 °C

# Molecular_Weight_Avg:
342.2965

# Molecular_Weight_Mono:
342.116211546

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1MUU

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451525

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.6

# Predicted_LogS:
0.38

# Predicted_Water_Solubility:
8.24e+02 g/l

# Primary_Accession_No:
DB02772

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936484

# PubChem_Substance_ID:
46506134

# RxList_Link:
http://www.rxlist.com/cgi/generic/venofer.htm

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02977

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@](CO)(O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:28 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Sucrose

# pKa_Isoelectric_Point:
12.6

# Drug_Target_10_Cellular_Location:
Secreted protein

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
Not Available

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
Z94043

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
sacB

# Drug_Target_10_Gene_Sequence:
>1422 bp
TTATTTGTTAACTGTTAATTGTCCTTGTTCAAGGATGCTGTCTTTGACAACAGATGTTTT
CTTGCCTTTGATGTTCAGCAGGAAGCTTGGCGCAAACGTTGATTGTTTGTCTGCGTAGAA
TCCTCTGTTTGTCATATAGCTTGTAATCACGACATTGTTTCCTTTCGCTTGAGGTACAGC
GAAGTGTGAGTAAGTAAAGGTTACATCGTTAGGATCAAGATCCATTTTTAACACAAGGCC
AGTTTTGTTCAGCGGCTTGTATGGGCCAGTTAAAGAATTAGAAACATAACCAAGCATGTA
AATATCGTTAGACGTAATGCCGTCAATCGTCATTTTTGATCCGCGGGAGTCAGTGAACAG
GTACCATTTGCCGTTCATTTTAAAGACGTTCGCGCGTTCAATTTCATCTGTTACTGTGTT
AGATGCAATCAGCGGTTTCATCACTTTTTTCAGTGTGTAATCATCGTTTAGCTCAATCAT
ACCGAGAGCGCCGTTTGCTAACTCAGCCGTGCGTTTTTTATCGCTTTGCAGAAGTTTTTG
ACTTTCTTGACGGAAGAATGATGTGCTTTTGCCATAGTATGCTTTGTTAAATAAAGATTC
TTCGCCTTGGTAGCCATCTTCAGTTCCAGTGTTTGCTTCAAATACTAAGTATTTGTGGCC
TTTATCTTCTACGTAGTGAGGATCTCTCAGCGTATGGTTGTCGCCTGAGCTGTAGTTGCC
TTCATCGATGAACTGCTGTACATTTTGATACGTTTTTCCGTCACCGTCAAAGATTGATTT
ATAATCCTCTACACCGTTGATGTTCAAAGAGCTGTCTGATGCTGATACGTTAACTTGTGC
AGTTGTCAGTGTTTGTTTGCCGTAATGTTTACCGGAGAAATCAGTGTAGAATAAACGGAT
TTTTCCGTCAGATGTAAATGTGGCTGAACCTGACCATTCTTGTGTTTGGTCTTTTAGGAT
AGAATCATTTGCATCGAATTTGTCGCTGTCTTTAAAGACGCGGCCAGCGTTTTTCCAGCT
GTCAATAGAAGTTTCGCCGACTTTTTGATAGAACATGTAAATCGATGTGTCATCCGCATT
TTTAGGATCTCCGGCTAATGCAAAGACGATGTGGTAGCCGTGATAGTTTGCGACAGTGCC
GTCAGCGTTTTGTAATGGCCAGCTGTCCCAAACGTCCAGGCCTTTTGCAGAAGAGATATT
TTTAATTGTGGACGAATCGAATTCAGGAACTTGATATTTTTCATTTTTTTGCTGTTCAGG
GATTTGCAGCATATCATGGCGTGTAATATGGGAAATGCCGTATGTTTCCTTATATGGCTT
TTGGTTCGTTTCTTTCGCAAACGCTTGAGTTGCGCCTCCTGCCAGCAGTGCGGTAGTAAA
GGTTAATACTGTTGCTTGTTTTGCAAACTTTTTGATGTTCAT

# Drug_Target_10_General_Function:
Involved in levansucrase activity

# Drug_Target_10_General_References:
2428811	Shimotsu H, Henner DJ: Modulation of Bacillus subtilis levansucrase gene expression by sucrose and regulation of the steady-state mRNA level by sacU and sacQ genes. J Bacteriol. 1986 Oct;168(1):380-8.
2993818	Steinmetz M, Le Coq D, Aymerich S, Gonzy-Treboul G, Gay P: The DNA sequence of the gene for the secreted Bacillus subtilis enzyme levansucrase and its genetic control sites. Mol Gen Genet. 1985;200(2):220-8.
6424671	Fouet A, Arnaud M, Klier A, Rapoport G: Characterization of the precursor form of the exocellular levansucrase from Bacillus subtilis. Biochem Biophys Res Commun. 1984 Mar 15;119(2):795-800.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
4748

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
52971

# Drug_Target_10_Name:
Levansucrase

# Drug_Target_10_Number_of_Residues:
473

# Drug_Target_10_PDB_ID:
1OYG

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF02435	Glyco_hydro_68

# Drug_Target_10_Protein_Sequence:
>Levansucrase
MNIKKFAKQATVLTFTTALLAGGATQAFAKETNQKPYKETYGISHITRHDMLQIPEQQKN
EKYQVPEFDSSTIKNISSAKGLDVWDSWPLQNADGTVANYHGYHIVFALAGDPKNADDTS
IYMFYQKVGETSIDSWKNAGRVFKDSDKFDANDSILKDQTQEWSGSATFTSDGKIRLFYT
DFSGKHYGKQTLTTAQVNVSASDSSLNINGVEDYKSIFDGDGKTYQNVQQFIDEGNYSSG
DNHTLRDPHYVEDKGHKYLVFEANTGTEDGYQGEESLFNKAYYGKSTSFFRQESQKLLQS
DKKRTAELANGALGMIELNDDYTLKKVMKPLIASNTVTDEIERANVFKMNGKWYLFTDSR
GSKMTIDGITSNDIYMLGYVSNSLTGPYKPLNKTGLVLKMDLDPNDVTFTYSHFAVPQAK
GNNVVITSYMTNRGFYADKQSTFAPSFLLNIKGKKTSVVKDSILEQGQLTVNK

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
1-29

# Drug_Target_10_Specific_Function:
Sucrose + (2,6-beta-D-fructosyl)(n) = glucose + (2,6-beta-D-fructosyl)(n+1)

# Drug_Target_10_SwissProt_ID:
P05655

# Drug_Target_10_SwissProt_Name:
SACB_BACSU

# Drug_Target_10_Synonyms:
Beta-D-fructofuranosyl transferase
EC 2.4.1.10
Levansucrase precursor
Sucrose 6-fructosyl transferase

# Drug_Target_10_Theoretical_pI:
6.62

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Cytoplasmic

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
Not Available

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
AY156923

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
blaCTX-M-27

# Drug_Target_11_Gene_Sequence:
>876 bp
ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTG
CTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTG
GAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAG
GTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCC
GCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATC
AAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATG
ACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAA
TTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGAT
GAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCG
AGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCAT
GCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGC
GCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGC
GGCGGCTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTG
GTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTG
GCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAA

# Drug_Target_11_General_Function:
Involved in beta-lactamase activity

# Drug_Target_11_General_References:
12775683	Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, De Champs C, Sirot J: Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother. 2003 Jul;52(1):29-35. Epub 2003 May 29.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
4818

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
30922

# Drug_Target_11_Name:
Beta-lactamase CTX-M-27

# Drug_Target_11_Number_of_Residues:
291

# Drug_Target_11_PDB_ID:
1YLW

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_11_Protein_Sequence:
>Beta-lactamase CTX-M-27
MVTKRVQRMMFAAAACIPLLLGSAPLYAQTSAVQQKLAALEKSSGGRLGVALIDTADNTQ
VLYRGDERFPMCSTSKVMAAAAVLKQSETQKQLLNQPVEIKPADLVNYNPIAEKHVNGTM
TLAELSAAALQYSDNTAMNKLIAQLGGPGGVTAFARAIGDETFRLDRTEPTLNTAIPGDP
RDTTTPRAMAQTLRQLTLGHALGETQRAQLVTWLKGNTTGAASIRAGLPTSWTVGDKTGS
GGYGTTNDIAVIWPQGRAPLVLVTYFTQPQQNAESRRDVLASAARIIAEGL

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Not Available

# Drug_Target_11_SwissProt_ID:
Q840M4

# Drug_Target_11_SwissProt_Name:
Q840M4_ECOLX

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
9.63

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
Y00337

# Drug_Target_12_GenBank_ID_Protein:
45268

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
algD

# Drug_Target_12_Gene_Sequence:
>1311 bp
ATGCGAATCAGCATCTTTGGTTTGGGCTATGTCGGTGCAGTATGTGCTGGCTGCCTGTCG
GCACGCGGTCATGAAGTCATTGGTGTGGATGTCTCCAGCACCAAGATCGACCTGATCAAC
CAGGGCAAGTCGCCCATCGTCGAACCGGGCCTGGAAGCGTTGTTGCAGCAAGGCCGGCAG
ACCGGACGGCTGTCGGGCACCACCGACTTCAAGAAGGCTGTGCTGGACTCCGACGTATCG
TTCATCTGCGTCGGCACGCCGAGCAAGAAGAACGGCGACCTGGACCTGGGCTACATCGAG
ACCGTCTGCCGCGAGATCGGCTTCGCCATCCGCGAGAAGTCCGAACGCCACACCGTGGTG
GTGCGCAGCACCGTACTGCCGGGCACCGTCAACAACGTGGTGATCCCGCTGATCGAGGAC
TGCTCGGGCAAGAAGGCCGGGGTCGACTTCGGCGTCGGCACCAACCCCGAATTCCTCCGC
GAGAGCACCGCGATCAAGGACTACGACTTCCCGCCGATGACCGTGATCGGCGAACTGGAC
AAGCAGACCGGCGACCTTCTCGAGGAAATCTACCGCGAGCTGGACGCGCCGATCATCCGC
AAGACCGTCGAGGTCGCCGAGATGATCAAGTACACCTGCAACGTCTGGCACGCCGCCAAG
GTCACCTTCGCCAACGAGATCGGCAACATCGCCAAGGCGGTCGGCGTCGACGGCCGCGAG
GTGATGGACGTGATCTGCCAGGACCACAAGCTCAACCTGTCGCGCTACTACATGCGTCCC
GGCTTCGCCTTCGGCGGCTCCTGCCTGCCCAAGGATGTACGCGCCCTCACCTATCGCGCC
AGCCAGCTGGACGTCGAGCACCCGATGCTCGGTTCGTTGATGCGCAGCAACTCCAACCAG
GTGCAGAAGGCCTTCGATCTCATCACCAGCCACGACACCCGCAAGGTCGGCCTGCTCGGC
CTGTCGTTCAAGGCCGGCACCGACGATTTGCGCGAAAGCCCGCTGGTGGAGCTGGCCGAG
ATGCTCATCGGCAAGGGCTACGAGTTCCGCATCTTCGACCGCAACGTCGAATACGCGCGT
GTCCACGGGGCCAACAAGGAATACATCGAGTCGAAGATCCCGCACGTCTCCTCGCTGCTG
GTCTCCGACCTCGACGAAGTGGTGGCGAGTTCCGATGTGCTGGTGCTGGGCAATGGCGAC
GAGCTGTTCGTCGACCTGGTGAACAAGACCCCGAGCGGCAAGAAGCTGGTCGACCTGGTG
GGCTTCATGCCGCACACCACCACTGCCCAGGCCGAGGGCATCTGCTGGTAG

# Drug_Target_12_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_12_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
12135385	Naught LE, Gilbert S, Imhoff R, Snook C, Beamer L, Tipton P: Allosterism and cooperativity in Pseudomonas aeruginosa GDP-mannose dehydrogenase. Biochemistry. 2002 Jul 30;41(30):9637-45.
12705829	Snook CF, Tipton PA, Beamer LJ: Crystal structure of GDP-mannose dehydrogenase: a key enzyme of alginate biosynthesis in P. aeruginosa. Biochemistry. 2003 Apr 29;42(16):4658-68.
1370473	Roychoudhury S, Chakrabarty K, Ho YK, Chakrabarty AM: Characterization of guanosine diphospho-D-mannose dehydrogenase from Pseudomonas aeruginosa. Structural analysis by limited proteolysis. J Biol Chem. 1992 Jan 15;267(2):990-6.
2470755	Roychoudhury S, May TB, Gill JF, Singh SK, Feingold DS, Chakrabarty AM: Purification and characterization of guanosine diphospho-D-mannose dehydrogenase. A key enzyme in the biosynthesis of alginate by Pseudomonas aeruginosa. J Biol Chem. 1989 Jun 5;264(16):9380-5.
3108855	Deretic V, Gill JF, Chakrabarty AM: Pseudomonas aeruginosa infection in cystic fibrosis: nucleotide sequence and transcriptional regulation of the algD gene. Nucleic Acids Res. 1987 Jun 11;15(11):4567-81.
8294014	Maharaj R, May TB, Wang SK, Chakrabarty AM: Sequence of the alg8 and alg44 genes involved in the synthesis of alginate by Pseudomonas aeruginosa. Gene. 1993 Dec 22;136(1-2):267-9.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
3367

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
47600

# Drug_Target_12_Name:
GDP-mannose 6-dehydrogenase

# Drug_Target_12_Number_of_Residues:
436

# Drug_Target_12_PDB_ID:
1MV8

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00984	UDPG_MGDP_dh
PF03720	UDPG_MGDP_dh_C
PF03721	UDPG_MGDP_dh_N

# Drug_Target_12_Protein_Sequence:
>GDP-mannose 6-dehydrogenase
MRISIFGLGYVGAVCAGCLSARGHEVIGVDVSSTKIDLINQGKSPIVEPGLEALLQQGRQ
TGRLSGTTDFKKAVLDSDVSFICVGTPSKKNGDLDLGYIETVCREIGFAIREKSERHTVV
VRSTVLPGTVNNVVIPLIEDCSGKKAGVDFGVGTNPEFLRESTAIKDYDFPPMTVIGELD
KQTGDLLEEIYRELDAPIIRKTVEVAEMIKYTCNVWHAAKVTFANEIGNIAKAVGVDGRE
VMDVICQDHKLNLSRYYMRPGFAFGGSCLPKDVRALTYRASQLDVEHPMLGSLMRSNSNQ
VQKAFDLITSHDTRKVGLLGLSFKAGTDDLRESPLVELAEMLIGKGYELRIFDRNVEYAR
VHGANKEYIESKIPHVSSLLVSDLDEVVASSDVLVLGNGDELFVDLVNKTPSGKKLVDLV
GFMPHTTTAQAEGICW

# Drug_Target_12_Reaction:
GDP-D-mannose + 2 NAD+ + H2O = GDP-D-mannuronate + 2 NADH + 2 H+

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Catalyzes the oxidation of guanosine diphospho-D-mannose (GDP-D-mannose) to GDP-D-mannuronic acid, a precursor for alginate polymerization. The alginate layer causes a mucoid phenotype and provides a protective barrier against host immune defenses and antibiotics

# Drug_Target_12_SwissProt_ID:
P11759

# Drug_Target_12_SwissProt_Name:
ALGD_PSEAE

# Drug_Target_12_Synonyms:
EC 1.1.1.132
GMD

# Drug_Target_12_Theoretical_pI:
5.35

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Cytoplasm

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
ACTA1

# Drug_Target_13_GenBank_ID_Gene:
J00068

# Drug_Target_13_GenBank_ID_Protein:
178029

# Drug_Target_13_GeneCard_ID:
ACTA1

# Drug_Target_13_Gene_Name:
ACTA1

# Drug_Target_13_Gene_Sequence:
>1134 bp
ATGTGCGACGAAGACGAGACCACCGCCCTCGTGTGCGACAATGGCTCCGGCCTGGTGAAA
GCCGGCTTCGCCGGGGATGACGCCCCTAGGGCCGTGTTCCCGTCCATCGTGGGCCGCCCC
CGACACCAGGGCGTCATGGTCGGTATGGGTCAGAAAGATTCCTACGTGGGCGACGAGGCT
CAGAGCAAGAGAGGTATCCTGACCCTGAAGTACCCTATCGAGCACGGCATCATCACCAAC
TGGGATGACATGGAGAAGATCTGGCACCACACCTTCTACAACGAGCTTCGCGTGGCTCCC
GAGGAGCACCCCACCCTGCTCACCGAAGCCCCCCTCAATCCCAAGGCCAACCGCGAGAAG
ATGACCCAGATCATGTTTGAGACCTTCAACGTGCCCGCCATGTACGTGGCCATCCAGGCC
GTGCTGTCCCTCTACGCCTCCGGCAGGACCACCGGCATCGTGCTGGACTCCGGCGACGGC
GTCACCCACAACGTGCCCATTTATGAGGGCTACGCGCTGCCGCACGCCATCATGCGCCTG
GACCTGGCGGGCCGCGATCTTACCGACTACCTGATGAAGATCCTCACTGAGCGTGGCTAC
TCCTTCGTGACCACAGCTGAGCGCGAGATCGTGCGCGACATCAAGGAGAAGCTGTGCTAC
GTGGCCCTGGACTTCGAGAACGAGATGGCGACGGCCGCCTCCTCCTCCTCCCTGGAAAAG
AGCTACGAGCTGCCAGACGGGCAGGTCATCACCATCGGCAACGAGCGCTTCCGCTGCCCG
GAGACGCTCTTCCAGCCCTCCTTCATCGGTATGGAGTCGGCGGGCATTCACGAGACCACC
TACAACAGCATCATGAAGTGTGACATCGACATCAGGAAGGACCTGTATGCCAACAACGTC
ATGTCGGGGGGCACCACGATGTACCCTGGGATCGCTGACCGCATGCAGAAAGAGATCACC
GCGCTGGCACCCAGCACCATGAAGATCAAGATCATCGCCCCGCCGGAGCGCAAATACTCG
GTGTGGATCGGCGGCTCCATCCTGGCCTCGCTGTCCACCTTCCAGCAGATGTGGATCACC
AAGCAGGAGTACGACGAGGCCGGCCCTTCCATCGTCCACCGCAAATGCTTCTAG

# Drug_Target_13_General_Function:
Cytoskeleton

# Drug_Target_13_General_References:
10508519	Nowak KJ, Wattanasirichaigoon D, Goebel HH, Wilce M, Pelin K, Donner K, Jacob RL, Hubner C, Oexle K, Anderson JR, Verity CM, North KN, Iannaccone ST, Muller CR, Nurnberg P, Muntoni F, Sewry C, Hughes I, Sutphen R, Lacson AG, Swoboda KJ, Vigneron J, Wallgren-Pettersson C, Beggs AH, Laing NG: Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet. 1999 Oct;23(2):208-12.
11166164	Jungbluth H, Sewry CA, Brown SC, Nowak KJ, Laing NG, Wallgren-Pettersson C, Pelin K, Manzur AY, Mercuri E, Dubowitz V, Muntoni F: Mild phenotype of nemaline myopathy with sleep hypoventilation due to a mutation in the skeletal muscle alpha-actin (ACTA1) gene. Neuromuscul Disord. 2001 Jan;11(1):35-40.
11333380	Ilkovski B, Cooper ST, Nowak K, Ryan MM, Yang N, Schnell C, Durling HJ, Roddick LG, Wilkinson I, Kornberg AJ, Collins KJ, Wallace G, Gunning P, Hardeman EC, Laing NG, North KN: Nemaline myopathy caused by mutations in the muscle alpha-skeletal-actin gene. Am J Hum Genet. 2001 Jun;68(6):1333-43. Epub 2001 Apr 27.
2907503	Taylor A, Erba HP, Muscat GE, Kedes L: Nucleotide sequence and expression of the human skeletal alpha-actin gene: evolution of functional regulatory domains. Genomics. 1988 Nov;3(4):323-36.
6190133	Hanauer A, Levin M, Heilig R, Daegelen D, Kahn A, Mandel JL: Isolation and characterization of cDNA clones for human skeletal muscle alpha actin. Nucleic Acids Res. 1983 Jun 11;11(11):3503-16.

# Drug_Target_13_HGNC_ID:
HGNC:129

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
3822

# Drug_Target_13_Locus:
1q42.13-q42.2

# Drug_Target_13_Molecular_Weight:
42052

# Drug_Target_13_Name:
Actin, alpha skeletal muscle

# Drug_Target_13_Number_of_Residues:
377

# Drug_Target_13_PDB_ID:
1IJJ

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00022	Actin

# Drug_Target_13_Protein_Sequence:
>Actin, alpha skeletal muscle
MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA
QSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREK
MTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRL
DLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEK
SYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNV
MSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIT
KQEYDEAGPSIVHRKCF

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells

# Drug_Target_13_SwissProt_ID:
P68133

# Drug_Target_13_SwissProt_Name:
ACTS_HUMAN

# Drug_Target_13_Synonyms:
Alpha-actin-1

# Drug_Target_13_Theoretical_pI:
5.05

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Periplasm

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
J01611

# Drug_Target_14_GenBank_ID_Protein:
145267

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
ampC

# Drug_Target_14_Gene_Sequence:
>1134 bp
ATGTTCAAAACGACGCTCTGCGCCTTATTAATTACCGCCTCTTGCTCCACATTTGCTGCC
CCTCAACAAATCAACGATATTGTGCATCGCACAATTACCCCGCTTATAGAGCAACAAAAG
ATCCCGGGTATGGCGGTGGCGGTAATTTATCAGGGTAAACCTTATTACTTTACCTGGGGC
TATGCGGACATCGCCAAAAAGCAGCCCGTCACACAGCAAACGTTGTTTGAGTTAGGTTCG
GTCAGCAAAACATTTACTGGCGTGCTTGGTGGCGACGCTATTGCTCGAGGGGAAATCAAG
TTAAGCGATCCCACAACAAAATACTGGCCTGAACTTACCGCTAAACAGTGGAATGGGATC
ACACTATTACATCTCGCAACCTACACTGCTGGCGGCCTGCCATTGCAGGTGCCGGATGAG
GTGAAATCCTCAAGCGACTTGCTGCGCTTCTATCAAAACTGGCAGCCTGCATGGGCTCCA
GGAACACAACGTCTGTATGCCAACTCCAGTATCGGTTTGTTCGGCGCACTGGCTGTGAAG
CCGTCTGGTTTGAGTTTTGAGCAGGCGATGCAAACTCGTGTCTTCCAGCCACTCAAACTC
AACCATACGTGGATTAATGTACCGCCCGCAGAAGAAAAGAATTACGCCTGGGGATATCGC
GAAGGTAAGGCAGTGCATGTTTCGCCTGGGGCGTTAGATGCTGAAGCTTATGGTGTGAAG
TCGACCATTGAAGATATGGCCCGCTGGGTGCAAAGCAATTTAAAACCCCTTGATATCAAT
GAGAAAACGCTTCAACAAGGGATACAACTGGCACAATCTCGCTACTGGCAAACCGGCGAT
ATGTATCAGGGCCTGGGCTGGGAAATGCTGGACTGGCCGGTAAATCCTGACAGCATCATT
AACGGCAGTGACAATAAAATTGCACTGGCAGCACGCCCCGTAAAAGCGATTACGCCCCCA
ACTCCTGCAGTACGCGCATCATGGGTACATAAAACAGGGGCGACCGGCGGATTTGGTAGC
TATGTCGCGTTTATTCCAGAAAAAGAGCTGGGTATCGTGATGCTGGCAAACAAAAACTAT
CCCAATCCAGCGAGAGTCGACGCCGCCTGGCAGATTCTTAACGCTCTACAGTAA

# Drug_Target_14_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_14_General_References:
10595535	Powers RA, Blazquez J, Weston GS, Morosini MI, Baquero F, Shoichet BK: The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci. 1999 Nov;8(11):2330-7.
11478888	Powers RA, Caselli E, Focia PJ, Prati F, Shoichet BK: Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design. Biochemistry. 2001 Aug 7;40(31):9207-14.
12144785	Beadle BM, Shoichet BK: Structural bases of stability-function tradeoffs in enzymes. J Mol Biol. 2002 Aug 9;321(2):285-96.
12526668	Morandi F, Caselli E, Morandi S, Focia PJ, Blazquez J, Shoichet BK, Prati F: Nanomolar inhibitors of AmpC beta-lactamase. J Am Chem Soc. 2003 Jan 22;125(3):685-95.
6795623	Jaurin B, Grundstrom T: ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4897-901.
7041115	Grundstrom T, Jaurin B: Overlap between ampC and frd operons on the Escherichia coli chromosome. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1111-5.
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9819201	Usher KC, Blaszczak LC, Weston GS, Shoichet BK, Remington SJ: Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry. 1998 Nov 17;37(46):16082-92.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
2478

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
41556

# Drug_Target_14_Name:
Beta-lactamase

# Drug_Target_14_Number_of_Residues:
377

# Drug_Target_14_PDB_ID:
1XGJ

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_14_Protein_Sequence:
>Beta-lactamase precursor
MFKTTLCALLITASCSTFAAPQQINDIVHRTITPLIEQQKIPGMAVAVIYQGKPYYFTWG
YADIAKKQPVTQQTLFELGSVSKTFTGVLGGDAIARGEIKLSDPTTKYWPELTAKQWNGI
TLLHLATYTAGGLPLQVPDEVKSSSDLLRFYQNWQPAWAPGTQRLYANSSIGLFGALAVK
PSGLSFEQAMQTRVFQPLKLNHTWINVPPAEEKNYAWGYREGKAVHVSPGALDAEAYGVK
STIEDMARWVQSNLKPLDINEKTLQQGIQLAQSRYWQTGDMYQGLGWEMLDWPVNPDSII
NGSDNKIALAARPVKAITPPTPAVRASWVHKTGATGGFGSYVAFIPEKELGIVMLANKNY
PNPARVDAAWQILNALQ

# Drug_Target_14_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_14_Signals:
1-19

# Drug_Target_14_Specific_Function:
This protein is a serine beta-lactamase with a substrate specificity for cephalosporins

# Drug_Target_14_SwissProt_ID:
P00811

# Drug_Target_14_SwissProt_Name:
AMPC_ECOLI

# Drug_Target_14_Synonyms:
Beta-lactamase precursor
Cephalosporinase
EC 3.5.2.6

# Drug_Target_14_Theoretical_pI:
9.07

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Not Available

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
BA000033

# Drug_Target_15_GenBank_ID_Protein:
21205025

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
nos

# Drug_Target_15_Gene_Sequence:
>1077 bp
ATGTTATTTAAAGAGGCTCAAGCTTTCATAGAAAACATGTATAAAGAGTGTCATTATGAA
ACGCAAATTATCAATAAACGTTTACATGACATTGAACTAGAAATAAAAGAAACTGGGACA
TATACACATACAGAAGAAGAACTTATTTATGGTGCTAAAATGGCTTGGCGTAATTCAAAT
CGTTGCATTGGTCGTTTATTTTGGGATTCGTTAAATGTCATTGATGCAAGAGATGTTACT
GACGAAGCATCGTTCTTATCATCAATTACTTATCATATTACACAGGCTACAAATGAAGGT
AAATTAAAGCCGTATATTACTATATATGCTCCAAAGGATGGACCTAAAATTTTCAACAAT
CAATTAATTCGCTATGCTGGCTATGACAATTGTGGTGATCCTGCTGAAAAAGAAGTTACA
CGCTTAGCAAATCACTTAGGTTGGAAAGGAAAAGGTACTAATTTTGACGTGTTACCACTG
ATTTACCAATTACCTAATGAGTCAGTTAAATTTTACGAATATCCTACTTCATTAATTAAA
GAAGTACCTATTGAACATAATCATTATCCAAAATTAAGAAAATTGAACTTAAAATGGTAT
GCAGTCCCTATCATTTCCAATATGGACTTAAAAATCGGTGGCATTGTATATCCAACTGCA
CCCTTTAACGGTTGGTATATGGTAACTGAAATTGGCGTACGTAACTTTATTGATGATTAC
CGTTACAATTTACTAGAAAAAGTTGCAGATGCGTTTGAATTTGATACACTTAAAAATAAT
TCATTTAATAAAGATCGAGCACTTGTTGAATTGAACTATGCTGTGTATCATTCCTTTAAA
AAAGAAGGCGTATCAATTGTCGATCATTTGACCGCTGCAAAGCAATTCGAACTATTCGAA
CGTAATGAAGCACAACAAGGTCGTCAAGTTACCGGAAAATGGTCTTGGCTAGCGCCGCCA
TTATCTCCAACATTGACGTCAAATTATCATCATGGATATGACAATACAGTAAAAGATCCA
AACTTTTTCTATAAAAAGAAAGAATCAAATGCTAACCAGTGCCCTTTCCATCATTAA

# Drug_Target_15_General_Function:
Involved in nitric-oxide synthase activity

# Drug_Target_15_General_References:
12044378	Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, Kuroda H, Cui L, Yamamoto K, Hiramatsu K: Genome and virulence determinants of high virulence community-acquired MRSA. Lancet. 2002 May 25;359(9320):1819-27.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
2701

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
41711

# Drug_Target_15_Name:
Nitric oxide synthase oxygenase

# Drug_Target_15_Number_of_Residues:
358

# Drug_Target_15_PDB_ID:
1MJT

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF02898	NO_synthase

# Drug_Target_15_Protein_Sequence:
>Nitric oxide synthase oxygenase
MLFKEAQAFIENMYKECHYETQIINKRLHDIELEIKETGTYTHTEEELIYGAKMAWRNSN
RCIGRLFWDSLNVIDARDVTDEASFLSSITYHITQATNEGKLKPYITIYAPKDGPKIFNN
QLIRYAGYDNCGDPAEKEVTRLANHLGWKGKGTNFDVLPLIYQLPNESVKFYEYPTSLIK
EVPIEHNHYPKLRKLNLKWYAVPIISNMDLKIGGIVYPTAPFNGWYMVTEIGVRNFIDDY
RYNLLEKVADAFEFDTLKNNSFNKDRALVELNYAVYHSFKKEGVSIVDHLTAAKQFELFE
RNEAQQGRQVTGKWSWLAPPLSPTLTSNYHHGYDNTVKDPNFFYKKKESNANQCPFHH

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Catalyzes the production of nitric oxide

# Drug_Target_15_SwissProt_ID:
P0A094

# Drug_Target_15_SwissProt_Name:
NOSO_STAAW

# Drug_Target_15_Synonyms:
EC 1.-.-.-
NOSoxy-like protein
SANOS

# Drug_Target_15_Theoretical_pI:
7.00

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Not Available

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
Not Available

# Drug_Target_16_GenBank_ID_Protein:
Not Available

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
LYZ

# Drug_Target_16_Gene_Sequence:
Not Available

# Drug_Target_16_General_Function:
Not Available

# Drug_Target_16_General_References:
Not Available

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
6252

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
Not Available

# Drug_Target_16_Name:
Lysozyme C

# Drug_Target_16_Number_of_Residues:
0

# Drug_Target_16_PDB_ID:
Not Available

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
Not Available

# Drug_Target_16_Protein_Sequence:
Not Available

# Drug_Target_16_Reaction:
Not Available

# Drug_Target_16_Signals:
Not Available

# Drug_Target_16_Specific_Function:
Not Available

# Drug_Target_16_SwissProt_ID:
P61626

# Drug_Target_16_SwissProt_Name:
LYSC_HUMAN

# Drug_Target_16_Synonyms:
Not Available

# Drug_Target_16_Theoretical_pI:
Not Available

# Drug_Target_16_Transmembrane_Regions:
Not Available

# Drug_Target_17_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
Not Available

# Drug_Target_17_GenBank_ID_Gene:
L08793

# Drug_Target_17_GenBank_ID_Protein:
143161

# Drug_Target_17_GeneCard_ID:
Not Available

# Drug_Target_17_Gene_Name:
maf

# Drug_Target_17_Gene_Sequence:
>570 bp
ATGACAAAACCGCTAATACTTGCATCACAATCTCCGCGCAGGAAAGAACTCCTCGATCTT
CTCCAGCTGCCCTACTCCATTATTGTCAGTGAAGTAGAAGAAAAATTAAATCGAAACTTT
TCACCAGAAGAAAACGTCCAATGGTTGGCAAAACAAAAAGCTAAGGCTGTAGCTGATCTC
CACCCGCATGCAATCGTTATCGGTGCTGATACAATGGTATGCCTTGACGGCGAATGTCTT
GGCAAACCGCAGGATCAAGAAGAAGCTGCTTCTATGCTGCGGAGGCTTTCAGGCCGAAGT
CACTCAGTAATAACCGCGGTCAGCATTCAAGCTGAAAATCACAGCGAGACTTTTTATGAT
AAGACAGAAGTTGCGTTTTGGTCCCTCAGTGAAGAAGAGATTTGGACATATATTGAAACA
AAAGAGCCGATGGATAAAGCAGGTGCATACGGCATCCAAGGAAGAGGCGCGCTTTTTGTA
AAGAAAATAGACGGAGATTATTATTCAGTCATGGGCCTTCCTATATCAAAAACAATGAGA
GCTCTTCGCCATTTTGATATAAGGGCATGA

# Drug_Target_17_General_Function:
Cell cycle control, cell division, chromosome partitioning

# Drug_Target_17_General_References:
10841541	Minasov G, Teplova M, Stewart GC, Koonin EV, Anderson WF, Egli M: Functional implications from crystal structures of the conserved Bacillus subtilis protein Maf with and without dUTP. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6328-33.
1400224	Levin PA, Margolis PS, Setlow P, Losick R, Sun D: Identification of Bacillus subtilis genes for septum placement and shape determination. J Bacteriol. 1992 Nov;174(21):6717-28.
8387996	Butler YX, Abhayawardhane Y, Stewart GC: Amplification of the Bacillus subtilis maf gene results in arrested septum formation. J Bacteriol. 1993 May;175(10):3139-45.
8419299	Margolis PS, Driks A, Losick R: Sporulation gene spoIIB from Bacillus subtilis. J Bacteriol. 1993 Jan;175(2):528-40.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_17_HGNC_ID:
Not Available

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
2780

# Drug_Target_17_Locus:
Not Available

# Drug_Target_17_Molecular_Weight:
21296

# Drug_Target_17_Name:
Septum formation protein Maf

# Drug_Target_17_Number_of_Residues:
189

# Drug_Target_17_PDB_ID:
1EXC

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF02545	Maf

# Drug_Target_17_Protein_Sequence:
>Septum formation protein Maf
MTKPLILASQSPRRKELLDLLQLPYSIIVSEVEEKLNRNFSPEENVQWLAKQKAKAVADL
HPHAIVIGADTMVCLDGECLGKPQDQEEAASMLRRLSGRSHSVITAVSIQAENHSETFYD
KTEVAFWSLSEEEIWTYIETKEPMDKAGAYGIQGRGALFVKKIDGDYYSVMGLPISKTMR
ALRHFDIRA

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Involved in septum formation

# Drug_Target_17_SwissProt_ID:
Q02169

# Drug_Target_17_SwissProt_Name:
MAF_BACSU

# Drug_Target_17_Synonyms:
Not Available

# Drug_Target_17_Theoretical_pI:
6.03

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Z29625

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
bgl3

# Drug_Target_1_Gene_Sequence:
>1440 bp
GTGGTCCCCGCAGCACAGCAGACCGCAACCGCCCCGGACGCCGCCCTCACCTTCCCCGAG
GGTTTCCTCTGGGGCTCGGCGACGGCCTCGTACCAGATCGAGGGTGCGGCCGCCGAGGAC
GGCCGGACGCCCTCCATCTGGGACACCTACGCCCGCACCCCGGGACGCGTCCGGAACGGC
GACACCGGTGACGTCGCCACCGACCACTACCACCGCTGGCGCGAGGACGTCGCCCTCATG
GCCGAACTGGGCCTGGGCGCCTACCGGTTCTCGCTCGCCTGGCCGCGCATCCAGCCCACC
GGCCGGGGCCCCGCCCTCCAGAAGGGTCTGGACTTCTACCGCCGGCTCGCCGACGAGCTC
CTCGCCAAGGGCATCCAGCCCGTCGCCACGCTCTACCACTGGGACCTGCCGCAGGAACTC
GAGAACCCCGGCGGCTGGCCCGAGCGCCCCACCGCCGAGCGGTTCGCCGAGTACGCCGCC
ATCGCCGCGGACGCCCTCGGCGACCGCGTGAAGACCTGGACCACCCTCAACGAGCCCTGG
TGCAGCGCGTTCCTCGGCTACGGCTCCGGCGTGCACGCCCCCGGCCGCACCGACCCGGTC
GCCGCCCTGCGCGCCGCGCACCACCTCAACCTGGGCCACGGCCTGGCCGTCCAGGCGCTG
CGCGACCGCCTCCCCGCCGACGCGCAGTGCTCGGTCACGCTCAACATCCACCACGTACGG
CCGCTCACCGACAGCGAGGCCGACGCCGACGCGGTCCGCCGGATCGACGCGCTCGCCAAC
CGGGTCTTCACCGGACCGATGCTCCAGGGCGCCTACCCGGAGGACCTCGTCAAGGACACC
GCCGGGCTGACCGACTGGTCCTTCGTCCGCGACGGCGACCTCCGACTGGCCCACCAGAAG
CTGGACTTCCTCGGCGTCAACTACTACTCCCCCACCCTCGTCTCCGAGGCCGACGGCAGC
GGCACGCACAACTCCGACGGACACGGCAGGAGCGCCCACAGCCCCTGGCCGGGCGCCGAC
CGGGTCGCGTTCCACCAACCGCCCGGCGAGACCACCGCCATGGGCTGGGCCGTCGACCCG
TCGGGCCTGTACGAGCTGCTGCGCCGCCTGTCCTCCGACTTCCCCGCGCTCCCGCTGGTC
ATCACCGAGAACGGCGCCGCCTTCCACGACTACGCGGACCCGGAGGGCAACGTCAACGAC
CCCGAGCGGATCGCCTACGTACGCGACCACCTGGCCGCCGTGCACCGGGCCATCAAGGAC
GGCTCGGACGTGCGCGGCTACTTCCTGTGGTCCCTGCTGGACAACTTCGAGTGGGCGCAC
GGCTACAGCAAGCGCTTCGGCGCCGTCTACGTCGACTACCCCACCGGCACGCGGATCCCG
AAGGCCAGCGCCCGCTGGTACGCCGAGGTGGCCCGCACGGGCGTCCTGCCCACCGCCTGA

# Drug_Target_1_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_1_General_References:
8055926	Perez-Pons JA, Cayetano A, Rebordosa X, Lloberas J, Guasch A, Querol E: A beta-glucosidase gene (bgl3) from Streptomyces sp. strain QM-B814. Molecular cloning, nucleotide sequence, purification and characterization of the encoded enzyme, a new member of family 1 glycosyl hydrolases. Eur J Biochem. 1994 Jul 15;223(2):557-65.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4810

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
52384

# Drug_Target_1_Name:
Beta-glucosidase

# Drug_Target_1_Number_of_Residues:
479

# Drug_Target_1_PDB_ID:
1GON

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00232	Glyco_hydro_1

# Drug_Target_1_Protein_Sequence:
>Beta-glucosidase
MVPAAQQTATAPDAALTFPEGFLWGSATASYQIEGAAAEDGRTPSIWDTYARTPGRVRNG
DTGDVATDHYHRWREDVALMAELGLGAYRFSLAWPRIQPTGRGPALQKGLDFYRRLADEL
LAKGIQPVATLYHWDLPQELENPGGWPERPTAERFAEYAAIAADALGDRVKTWTTLNEPW
CSAFLGYGSGVHAPGRTDPVAALRAAHHLNLGHGLAVQALRDRLPADAQCSVTLNIHHVR
PLTDSEADADAVRRIDALANRVFTGPMLQGAYPEDLVKDTAGLTDWSFVRDGDLRLAHQK
LDFLGVNYYSPTLVSEADGSGTHNSDGHGRSAHSPWPGADRVAFHQPPGETTAMGWAVDP
SGLYELLRRLSSDFPALPLVITENGAAFHDYADPEGNVNDPERIAYVRDHLAAVHRAIKD
GSDVRGYFLWSLLDNFEWAHGYSKRFGAVYVDYPTGTRIPKASARWYAEVARTGVLPTA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q59976

# Drug_Target_1_SwissProt_Name:
Q59976_STRSQ

# Drug_Target_1_Synonyms:
EC 3.2.1.21

# Drug_Target_1_Theoretical_pI:
5.79

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
Not Available

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AJ011781

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ams

# Drug_Target_2_Gene_Sequence:
>1911 bp
ATGTTGACCCCCACGCAGCAAGTCGGTTTGATTTTACAGTACCTCAAAACACGCATCTTG
GACATCTACACGCCCGAACAGCGCGCCGGCATCGAAAAATCCGAAGACTGGCGGCAGTTT
TCGCGCCGCATGGATACGCATTTCCCCAAACTGATGAACGAACTCGACAGCGTGTACGGC
AACAACGAAGCCCTGCTGCCTATGCTGGAAATGCTGCTGGCGCAGGCATGGCAAAGCTAT
TCCCAACGCAACTCATCCTTAAAAGATATCGATATCGCGCGCGAAAACAACCCCGATTGG
ATTTTGTCCAACAAACAAGTCGGCGGCGTGTGCTACGTTGATTTGTTTGCCGGCGATTTG
AAGGGCTTGAAAGATAAAATTCCTTATTTTCAAGAGCTTGGTTTGACTTATCTGCACCTG
ATGCCGCTGTTTAAATGCCCTGAAGGCAAAAGCGACGGCGGCTATGCGGTCAGCAGCTAC
CGCGATGTCAATCCGGCACTGGGCACAATAGGCGACTTGCGCGAAGTCATTGCTGCGCTG
CACGAAGCCGGCATTTCCGCCGTCGTCGATTTTATCTTCAACCACACCTCCAACGAACAC
GAATGGGCGCAACGCTGCGCCGCCGGCGACCCGCTTTTCGACAATTTCTACTATATTTTC
CCCGACCGCCGGATGCCCGACCAATACGACCGCACCCTGCGCGAAATCTTCCCCGACCAG
CACCCGGGCGGCTTCTCGCAACTGGAAGACGGACGCTGGGTGTGGACGACCTTCAATTCC
TTCCAATGGGACTTGAATTACAGCAACCCGTGGGTATTCCGCGCAATGGCGGGCGAAATG
CTGTTCCTTGCCAACTTGGGCGTTGACATCCTGCGTATGGATGCGGTTGCCTTTATTTGG
AAACAAATGGGGACAAGCTGCGAAAACCTGCCGCAGGCGCACGCCCTCATCCGCGCGTTC
AATGCCGTTATGCGTATTGCCGCGCCCGCCGTGTTCTTCAAATCCGAAGCCATCGTCCAC
CCCGACCAAGTCGTCCAATACATCGGGCAGGACGAATGCCAAATCGGTTACAACCCCCTG
CAAATGGCATTGTTGTGGAACACCCTTGCCACGCGCGAAGTCAACCTGCTCCATCAGGCG
CTGACCTACCGCCACAACCTGCCCGAGCATACCGCCTGGGTCAACTACGTCCGCAGCCAC
GACGACATCGGCTGGACGTTTGCCGATGAAGACGCGGCATATCTGGGCATAAGCGGCTAC
GACCACCGCCAATTCCTCAACCGCTTCTTCGTCAACCGTTTCGACGGCAGCTTCGCTCGT
GGCGTACCGTTCCAATACAACCCAAGCACAGGCGACTGCCGTGTCAGTGGTACAGCCGCG
GCATTGGTCGGCTTGGCGCAAGACGATCCCCACGCCGTTGACCGCATCAAACTCTTGTAC
AGCATTGCTTTGAGTACCGGCGGTCTGCCGCTGATTTACCTAGGCGACGAAGTGGGTACG
CTCAATGACGACGACTGGTCGCAAGACAGCAATAAGAGCGACGACAGCCGTTGGGCGCAC
CGTCCGCGCTACAACGAAGCCCTGTACGCGCAACGCAACGATCCGTCGACCGCAGCCGGG
CAAATCTATCAGGGCTTGCGCCATATGATTGCCGTCCGCCAAAGCAATCCGCGCTTCGAC
GGCGGCAGGCTGGTTACATTCAACACCAACAACAAGCACATCATCGGCTACATCCGCAAC
AATGCGCTTTTGGCATTCGGTAACTTCAGCGAATATCCGCAAACCGTTACCGCGCATACC
CTGCAAGCCATGCCCTTCAAGGCGCACGACCTCATCGGTGGCAAAACTGTCAGCCTGAAT
CAGGATTTGACGCTTCAGCCCTATCAGGTCATGTGGCTCGAAATCGCCTGA

# Drug_Target_2_General_Function:
Involved in catalytic activity

# Drug_Target_2_General_References:
10767427	Potocki de Montalk G, Remaud-Simeon M, Willemot RM, Sarcabal P, Planchot V, Monsan P: Amylosucrase from Neisseria polysaccharea: novel catalytic properties. FEBS Lett. 2000 Apr 14;471(2-3):219-23.
10828446	Sarcabal P, Remaud-Simeon M, Willemot R, Potocki de Montalk G, Svensson B, Monsan P: Identification of key amino acid residues in Neisseria polysaccharea amylosucrase. FEBS Lett. 2000 May 26;474(1):33-7.
12517860	Zhu P, Tsang RS, Tsai CM: Nonencapsulated Neisseria meningitidis strain produces amylopectin from sucrose: altering the concept for differentiation between N. meningitidis and N. polysaccharea. J Clin Microbiol. 2003 Jan;41(1):273-8.
9882648	De Montalk GP, Remaud-Simeon M, Willemot RM, Planchot V, Monsan P: Sequence analysis of the gene encoding amylosucrase from Neisseria polysaccharea and characterization of the recombinant enzyme. J Bacteriol. 1999 Jan;181(2):375-81.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4811

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
72344

# Drug_Target_2_Name:
Amylosucrase

# Drug_Target_2_Number_of_Residues:
636

# Drug_Target_2_PDB_ID:
1MW3

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00128	Alpha-amylase

# Drug_Target_2_Protein_Sequence:
>Amylosucrase
MLTPTQQVGLILQYLKTRILDIYTPEQRAGIEKSEDWRQFSRRMDTHFPKLMNELDSVYG
NNEALLPMLEMLLAQAWQSYSQRNSSLKDIDIARENNPDWILSNKQVGGVCYVDLFAGDL
KGLKDKIPYFQELGLTYLHLMPLFKCPEGKSDGGYAVSSYRDVNPALGTIGDLREVIAAL
HEAGISAVVDFIFNHTSNEHEWAQRCAAGDPLFDNFYYIFPDRRMPDQYDRTLREIFPDQ
HPGGFSQLEDGRWVWTTFNSFQWDLNYSNPWVFRAMAGEMLFLANLGVDILRMDAVAFIW
KQMGTSCENLPQAHALIRAFNAVMRIAAPAVFFKSEAIVHPDQVVQYIGQDECQIGYNPL
QMALLWNTLATREVNLLHQALTYRHNLPEHTAWVNYVRSHDDIGWTFADEDAAYLGISGY
DHRQFLNRFFVNRFDGSFARGVPFQYNPSTGDCRVSGTAAALVGLAQDDPHAVDRIKLLY
SIALSTGGLPLIYLGDEVGTLNDDDWSQDSNKSDDSRWAHRPRYNEALYAQRNDPSTAAG
QIYQGLRHMIAVRQSNPRFDGGRLVTFNTNNKHIIGYIRNNALLAFGNFSEYPQTVTAHT
LQAMPFKAHDLIGGKTVSLNQDLTLQPYQVMWLEIA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the synthesis of alpha-glucan from sucrose. Catalyzes, in addition, sucrose hydrolysis, maltose and maltotriose synthesis by successive transfers of the glucosyl moiety of sucrose onto the released glucose, and finally turanose and trehalulose synthesis, these two sucrose isomers being obtained by glucosyl transfer onto fructose

# Drug_Target_2_SwissProt_ID:
Q9ZEU2

# Drug_Target_2_SwissProt_Name:
AMYS_NEIPO

# Drug_Target_2_Synonyms:
EC 2.4.1.4

# Drug_Target_2_Theoretical_pI:
5.55

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AF252621

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
blaCTX-M-9a

# Drug_Target_3_Gene_Sequence:
>876 bp
ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTG
CTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTG
GAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAG
GTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCC
GCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATC
AAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATG
ACGCTGGCAGAGCTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAA
TTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGAT
GAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCG
AGAGACACCACCACGCCGCGGGCGATGGCACAGACGTTGCGTCAGCTTACGCTGGGTCAT
GCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGC
GCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGCAGGTGATAAGACCGGCAGC
GGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTG
GTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTG
GCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAA

# Drug_Target_3_General_Function:
Involved in beta-lactamase activity

# Drug_Target_3_General_References:
10858363	Sabate M, Tarrago R, Navarro F, Miro E, Verges C, Barbe J, Prats G: Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing beta-lactamase (CTX-M-9) from Escherichia coli in Spain. Antimicrob Agents Chemother. 2000 Jul;44(7):1970-3.
11850241	Chanawong A, M'Zali FH, Heritage J, Xiong JH, Hawkey PM: Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother. 2002 Mar;46(3):630-7.
12007800	Saladin M, Cao VT, Lambert T, Donay JL, Herrmann JL, Ould-Hocine Z, Verdet C, Delisle F, Philippon A, Arlet G: Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett. 2002 Apr 9;209(2):161-8.
12121950	Sabate M, Navarro F, Miro E, Campoy S, Mirelis B, Barbe J, Prats G: Novel complex sul1-type integron in Escherichia coli carrying bla(CTX-M-9). Antimicrob Agents Chemother. 2002 Aug;46(8):2656-61.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4629

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
30952

# Drug_Target_3_Name:
Beta-lactamase CTX-M-9a

# Drug_Target_3_Number_of_Residues:
291

# Drug_Target_3_PDB_ID:
1YMX

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_3_Protein_Sequence:
>Beta-lactamase CTX-M-9a
MVTKRVQRMMFAAAACIPLLLGSAPLYAQTSAVQQKLAALEKSSGGRLGVALIDTADNTQ
VLYRGDERFPMCSTSKVMAAAAVLKQSETQKQLLNQPVEIKPADLVNYNPIAEKHVNGTM
TLAELSAAALQYSDNTAMNKLIAQLGGPGGVTAFARAIGDETFRLDRTEPTLNTAIPGDP
RDTTTPRAMAQTLRQLTLGHALGETQRAQLVTWLKGNTTGAASIRAGLPTSWTAGDKTGS
GDYGTTNDIAVIWPQGRAPLVLVTYFTQPQQNAESRRDVLASAARIIAEGL

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
Q9L5C8

# Drug_Target_3_SwissProt_Name:
Q9L5C8_ECOLX

# Drug_Target_3_Synonyms:
Beta-lactamase
Betalactamase CTX-M-9
CTX-M-9 beta-lactamase

# Drug_Target_3_Theoretical_pI:
9.38

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
Not Available

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AF252622

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
blaCTX-M-14

# Drug_Target_4_Gene_Sequence:
>876 bp
ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTG
CTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTG
GAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAG
GTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCC
GCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATC
AAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATG
ACGCTGGCAGAACTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAA
TTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGAT
GAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCG
AGAGACACCACCACGCCGCGGGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGGTCAT
GCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGC
GCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTGGGTGATAAGACCGGCAGC
GGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTG
GTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTG
GCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAA

# Drug_Target_4_General_Function:
Involved in beta-lactamase activity

# Drug_Target_4_General_References:
11850241	Chanawong A, M'Zali FH, Heritage J, Xiong JH, Hawkey PM: Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother. 2002 Mar;46(3):630-7.
12007800	Saladin M, Cao VT, Lambert T, Donay JL, Herrmann JL, Ould-Hocine Z, Verdet C, Delisle F, Philippon A, Arlet G: Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett. 2002 Apr 9;209(2):161-8.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
4812

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
30980

# Drug_Target_4_Name:
Extended-spectrum beta-lactamase CTX-M-14

# Drug_Target_4_Number_of_Residues:
291

# Drug_Target_4_PDB_ID:
1YLZ

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_4_Protein_Sequence:
>Extended-spectrum beta-lactamase CTX-M-14
MVTKRVQRMMFAAAACIPLLLGSAPLYAQTSAVQQKLAALEKSSGGRLGVALIDTADNTQ
VLYRGDERFPMCSTSKVMAAAAVLKQSETQKQLLNQPVEIKPADLVNYNPIAEKHVNGTM
TLAELSAAALQYSDNTAMNKLIAQLGGPGGVTAFARAIGDETFRLDRTEPTLNTAIPGDP
RDTTTPRAMAQTLRQLTLGHALGETQRAQLVTWLKGNTTGAASIRAGLPTSWTVGDKTGS
GDYGTTNDIAVIWPQGRAPLVLVTYFTQPQQNAESRRDVLASAARIIAEGL

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
Q9L5C7

# Drug_Target_4_SwissProt_Name:
Q9L5C7_ECOLX

# Drug_Target_4_Synonyms:
CTX-M-14 beta-lactamase
Class A beta-lactamase
Extended spectrum betalactamase CTX-M-14b
TOHO-2 like beta- lactamase

# Drug_Target_4_Theoretical_pI:
9.38

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
U73860

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
hmuO

# Drug_Target_5_Gene_Sequence:
>648 bp
ATGACCACTGCAACCGCAGGCCTCGCTGTCGAACTCAAGCAGTCCACCGCACAAGCCCAC
GAAAAAGCTGAGCACTCCACCTTCATGAGCGACCTGCTAAAAGGTCGCTTGGGGGTAGCG
GAATTTACTCGTCTGCAGGAGCAAGCATGGTTGTTCTACACGGCACTAGAGCAGGCAGTA
GATGCCGTGCGTGCCAGCGGATTTGCGGAGTCCCTTCTCGATCCCGCTCTCAACCGTGCT
GAGGTTTTGGCACGCGACCTAGACAAGCTAAACGGTAGTAGTGAGTGGCGATCACGCATC
ACAGCATCGCCAGCTGTTATTGATTACGTGAATCGTCTTGAAGAAATCCGCGACAATGTT
GACGGCCCAGCGCTAGTTGCTCACCACTACGTGCGCTACCTCGGGGATCTCTCGGGCGGA
CAGGTTATCGCACGTATGATGCAGCGCCACTACGGCGTTGATCCTGAAGCCCTAGGTTTC
TACCACTTCGAGGGGATCGCCAAGCTCAAGGTCTACAAGGATGAGTACCGTGAAAAGCTC
AACAACCTAGAGCTTAGCGATGAACAGCGTGAGCACCTTTTGAAAGAAGCAACCGATGCT
TTCGTTTTCAACCACCAAGTTTTCGCAGATTTGGGTAAAGGCCTGTAA

# Drug_Target_5_General_Function:
Involved in heme oxygenase (decyclizing) activity

# Drug_Target_5_General_References:
14602910	Cerdeno-Tarraga AM, Efstratiou A, Dover LG, Holden MT, Pallen M, Bentley SD, Besra GS, Churcher C, James KD, De Zoysa A, Chillingworth T, Cronin A, Dowd L, Feltwell T, Hamlin N, Holroyd S, Jagels K, Moule S, Quail MA, Rabbinowitsch E, Rutherford KM, Thomson NR, Unwin L, Whitehead S, Barrell BG, Parkhill J: The complete genome sequence and analysis of Corynebacterium diphtheriae NCTC13129. Nucleic Acids Res. 2003 Nov 15;31(22):6516-23.
9006041	Schmitt MP: Utilization of host iron sources by Corynebacterium diphtheriae: identification of a gene whose product is homologous to eukaryotic heme oxygenases and is required for acquisition of iron from heme and hemoglobin. J Bacteriol. 1997 Feb;179(3):838-45.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
4813

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
24116

# Drug_Target_5_Name:
Heme oxygenase

# Drug_Target_5_Number_of_Residues:
215

# Drug_Target_5_PDB_ID:
1V8X

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF01126	Heme_oxygenase

# Drug_Target_5_Protein_Sequence:
>Heme oxygenase
MTTATAGLAVELKQSTAQAHEKAEHSTFMSDLLEGRLGVAEFTRLQEQAWLFYTALEQAA
DAVRASGFAESLLDPALNRAEVLARDLDKLNDGSEWRSRITASPAVIDYVNRLEEIRDNV
DGPALVAHHYVRYLGDLSGGQVIARMMQRHYGVDPEALGFYHFEGIAKLKVYKDEYREKL
NNLELSDEQRENLLKEATDAFVFNHQVFADLGKGL

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Allows the bacteria to use the host heme as an iron source. Involved in the oxidation of heme and subsequent release of iron from the heme moiety

# Drug_Target_5_SwissProt_ID:
P71119

# Drug_Target_5_SwissProt_Name:
HMUO_CORDI

# Drug_Target_5_Synonyms:
EC 1.14.99.3

# Drug_Target_5_Theoretical_pI:
4.79

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
ATOX1

# Drug_Target_6_GenBank_ID_Gene:
U70660

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
ATOX1

# Drug_Target_6_Gene_Sequence:
>207 bp
ATGCCGAAGCACGAGTTCTCTGTGGACATGACCTGTGGAGGCTGTGCTGAAGCTGTCTCT
CGGGTCCTCAATAAGCTTGGAGGAGTTAAGTATGACATTGACCTGCCCAACAAGAAGGTC
TGCATTGAATCTGAGCACAGCATGGACACTCTGCTTGCAACCCTGAAGAAAACAGGAAAG
ACTGTTTCCTACCTTGGCCTTGAGTAG

# Drug_Target_6_General_Function:
Involved in metal ion binding

# Drug_Target_6_General_References:
10966647	Wernimont AK, Huffman DL, Lamb AL, O'Halloran TV, Rosenzweig AC: Structural basis for copper transfer by the metallochaperone for the Menkes/Wilson disease proteins. Nat Struct Biol. 2000 Sep;7(9):766-71.
9083055	Klomp LW, Lin SJ, Yuan DS, Klausner RD, Culotta VC, Gitlin JD: Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J Biol Chem. 1997 Apr 4;272(14):9221-6.

# Drug_Target_6_HGNC_ID:
HGNC:798

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
4814

# Drug_Target_6_Locus:
5q32

# Drug_Target_6_Molecular_Weight:
7402

# Drug_Target_6_Name:
Copper transport protein ATOX1

# Drug_Target_6_Number_of_Residues:
68

# Drug_Target_6_PDB_ID:
1FE0

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00403	HMA

# Drug_Target_6_Protein_Sequence:
>Copper transport protein ATOX1
MPKHEFSVDMTCGGCAEAVSRVLNKLGGVKYDIDLPNKKVCIESEHSMDTLLATLKKTGK
TVSYLGLE

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Could bind and deliver cytosolic copper to the copper ATPase proteins. May be important in cellular antioxidant defense

# Drug_Target_6_SwissProt_ID:
O00244

# Drug_Target_6_SwissProt_Name:
ATOX1_HUMAN

# Drug_Target_6_Synonyms:
Metal transport protein ATX1

# Drug_Target_6_Theoretical_pI:
7.35

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
Not Available

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
C22orf28

# Drug_Target_7_Gene_Sequence:
Not Available

# Drug_Target_7_General_Function:
Not Available

# Drug_Target_7_General_References:
Not Available

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
6952

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
Not Available

# Drug_Target_7_Name:
UPF0027 protein C22orf28

# Drug_Target_7_Number_of_Residues:
0

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
Not Available

# Drug_Target_7_Protein_Sequence:
Not Available

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
Not Available

# Drug_Target_7_Specific_Function:
Not Available

# Drug_Target_7_SwissProt_ID:
Q9Y3I0

# Drug_Target_7_SwissProt_Name:
RTCB_HUMAN

# Drug_Target_7_Synonyms:
Not Available

# Drug_Target_7_Theoretical_pI:
Not Available

# Drug_Target_7_Transmembrane_Regions:
Not Available

# Drug_Target_8_Cellular_Location:
Cellular thylakoid membrane

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
Not Available

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
Not Available

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
Not Available

# Drug_Target_8_Gene_Sequence:
Not Available

# Drug_Target_8_General_Function:
Not Available

# Drug_Target_8_General_References:
Not Available

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
4816

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
35348

# Drug_Target_8_Name:
Orange carotenoid-binding protein

# Drug_Target_8_Number_of_Residues:
317

# Drug_Target_8_PDB_ID:
1M98

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF02136	NTF2
PF09150	Carot_N

# Drug_Target_8_Protein_Sequence:
>Orange carotenoid-binding protein
MPFTIDTARSIFPETLAADVVPATIARFKQLSAEDQLALIWFAYLEMGKTITIAAPGAAN
MQFAENTLQEIRQMTPLQQTQAMCDLANRTDTPICRTYASWSPNIKLGFWYELGRFMDQG
LVAPIPEGYKLSANANAILVTIQGIDPGQQITVLRNCVVDMGFDTSKLGSYQRVAEPVVP
PQEMSQRTKVQIEGVTNSTVLQYMDNLNANDFDNLISLFAEDGALQPPFQKPIVGKENTL
RFFREECQNLKLIPERGVSEPTEDGYTQIKVTGKVQTPWFGGNVGMNIAWRFLLNPENKV
FFVAIDLLASPKELLNL

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Acts as a photo-protectant. Essential for inhibiting white and blue-green light non-photochemical quenching (NPQ). Binding carotenoids improves OCP's intrinsic photoprotectant activity by broadening its absorption spectrum and facilitating the dissipation of absorbed energy

# Drug_Target_8_SwissProt_ID:
P83689

# Drug_Target_8_SwissProt_Name:
OCP_SPIMA

# Drug_Target_8_Synonyms:
OCP

# Drug_Target_8_Theoretical_pI:
4.54

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cell outer membrane

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
Not Available

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
X57400

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
scrY

# Drug_Target_9_Gene_Sequence:
>1518 bp
ATGTACAGAAAAAGCACACTTGCGATGCTTATCGCTTTGCTAACCAGCGCTGCCTCAGCC
CATGCGCAAACGGATATAAGCACCATTGAAGCCCGACTCAACGCGCTGGAAAAACGCCTG
CAGGAGGCAGAAAACAGGGCGCAAACGGCGGAAAACCGCGCCGGGGCGGCGGAGAAAAAA
GTTCAGCAACTCACCGCGCAGCAGCAAAAAAACCAGAACTCGACTCAGGAAGTGGCTCAG
CGTACCGCCAGACTTGAGAAAAAAGCCGATGACAAAAGCGGATTTGAGTTTCACGGTTAC
GCCCGCTCCGGCGTGATAATGAATGATTCCGGCGCCAGCACCAAATCCGGAGCCTACATA
ACGCCGGCAGGTGAAACCGGCGGAGCTATCGGCCGTCTGGGAAACCAGGCCGATACCTAT
GTTGAAATGAATCTTGAACATAAGCAGACCCTGGATAATGGGGCCACGACCCGCTTTAAG
GTGATGGTCGCCGACGGGCAAACCTCTTATAACGACTGGACTGCAAGCACCAGCGATCTG
AACGTTCGTCAGGCCTTTGTCGAATTGGGTAACCTGCCGACGTTCGCTGGGCCATTTAAG
GGCTCCACCCTGTGGGCCGGGAAACGTTTCGACCGCGACAATTTCGATATTCACTGGATT
GACTCTGATGTCGTGTTCCTCGCCGGTACCGGTGGTGGTATCTATGACGTGAAGTGGAAC
GACGGCCTGCGGAGTAATTTCTCCCTGTACGGGCGTAACTTCGGCGACATTGATGATTCC
AGCAACAGCGTGCAGAACTATATCCTCACCATGAATCACTTCGCAGGTCCGCTGCAGATG
ATGGTCAGCGGTCTGCGGGCGAAGGATAACGACGAGCGTAAAGATAGCAACGGCAATCTG
GCAAAAGGCGATGCGGCAAACACCGGCGTGCATGCGCTGCTCGGCCTGCATAACGACAGT
TTCTACGGCCTGCGCGACGGTAGCAGTAAAACCGCTCTGCTTTATGGTCATGGTCTGGGC
GCAGAGGTTAAAGGTATCGGATCTGATGGCGCACTTCGTCCGGGAGCCGACACATGGCGC
ATTGCCAGTTACGGCACCACGCCGCTCAGCGAAAACTGGTCTGTTGCCCCGGCAATGCTG
GCGCAACGCAGTAAAGACCGCTATGCCGATGGCGACAGCTATCAGTGGGCAACATTCAAC
CTGCGTCTGATTCAGGCAATCAATCAGAATTTCGCTCTCGCCTACGAAGGCAGCTACCAG
TACATGGATCTTAAACCCGAAGGTTATAACGATCGTCAGGCGGTGAACGGTAGCTTCTAC
AAGCTCACCTTCGCCCCGACATTTAAGGTCGGCAGTATCGGTGATTTCTTCAGTCGCCCG
GAGATTCGTTTCTATACCTCCTGGATGGACTGGAGCAAAAAACTGAATAATTACGCCAGC
GACGACGCCCTGGGCAGTGACGGTTTTAACTCGGGCGGCGAATGGTCTTTCGGTGTGCAG
ATGGAAACCTGGTTCTGA

# Drug_Target_9_General_Function:
Involved in sugar:hydrogen ion symporter activity

# Drug_Target_9_General_References:
1649946	Schmid K, Ebner R, Jahreis K, Lengeler JW, Titgemeyer F: A sugar-specific porin, ScrY, is involved in sucrose uptake in enteric bacteria. Mol Microbiol. 1991 Apr;5(4):941-50.
1846143	Hardesty C, Ferran C, DiRienzo JM: Plasmid-mediated sucrose metabolism in Escherichia coli: characterization of scrY, the structural gene for a phosphoenolpyruvate-dependent sucrose phosphotransferase system outer membrane porin. J Bacteriol. 1991 Jan;173(2):449-56.
9437428	Forst D, Welte W, Wacker T, Diederichs K: Structure of the sucrose-specific porin ScrY from Salmonella typhimurium and its complex with sucrose. Nat Struct Biol. 1998 Jan;5(1):37-46.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
4817

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
55468

# Drug_Target_9_Name:
Sucrose porin

# Drug_Target_9_Number_of_Residues:
505

# Drug_Target_9_PDB_ID:
1OH2

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF02264	LamB

# Drug_Target_9_Protein_Sequence:
>Sucrose porin
MYRKSTLAMLIALLTSAASAHAQTDISTIEARLNALEKRLQEAENRAQTAENRAGAAEKK
VQQLTAQQQKNQNSTQEVAQRTARLEKKADDKSGFEFHGYARSGVIMNDSGASTKSGAYI
TPAGETGGAIGRLGNQADTYVEMNLEHKQTLDNGATTRFKVMVADGQTSYNDWTASTSDL
NVRQAFVELGNLPTFAGPFKGSTLWAGKRFDRDNFDIHWIDSDVVFLAGTGGGIYDVKWN
DGLRSNFSLYGRNFGDIDDSSNSVQNYILTMNHFAGPLQMMVSGLRAKDNDERKDSNGNL
AKGDAANTGVHALLGLHNDSFYGLRDGSSKTALLYGHGLGAEVKGIGSDGALRPGADTWR
IASYGTTPLSENWSVAPAMLAQRSKDRYADGDSYQWATFNLRLIQAINQNFALAYEGSYQ
YMDLKPEGYNDRQAVNGSFYKLTFAPTFKVGSIGDFFSRPEIRFYTSWMDWSKKLNNYAS
DDALGSDGFNSGGEWSFGVQMETWF

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
1-22

# Drug_Target_9_Specific_Function:
Porin for sucrose uptake

# Drug_Target_9_SwissProt_ID:
P22340

# Drug_Target_9_SwissProt_Name:
SCRY_SALTY

# Drug_Target_9_Synonyms:
Sucrose porin precursor

# Drug_Target_9_Theoretical_pI:
5.92

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB02772
